stockportfolio.pro
Xenon Pharmaceuticals Inc. (XENE)
Healthcare · Biotechnology · NasdaqGM
Xenon Pharmaceuticals Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.80M | $311,000 | $0 | $6.83M | $32.17M | $18.44M | $9.43M | $0 | $0 | $7.50M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-23.00M | $-30.70M | $-34.50M | $-41.59M | $-28.84M | $-78.88M | $-125.37M | $-182.39M | $-234.33M | $-345.91M |
| Net margin | -1275.5% | -9872.7% | — | -609.1% | -89.7% | -427.8% | -1328.9% | — | — | -4612.1% |
Source: Xenon Pharmaceuticals Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Xenon Pharmaceuticals Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track XENE in your portfolio →
Xenon Pharmaceuticals Inc. financial history by metric
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. — frequently asked questions
What is Xenon Pharmaceuticals Inc.'s revenue?
Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.50M for fiscal year 2025, according to its SEC filings.
Is Xenon Pharmaceuticals Inc. profitable?
No — XENE reported a net loss of $-345.91M in fiscal 2025.
What is XENE's P/E ratio?
Xenon Pharmaceuticals Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Xenon Pharmaceuticals Inc. growing?
XENE's revenue grew at roughly -25.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Xenon Pharmaceuticals Inc. have?
As of fiscal year 2025, XENE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Xenon Pharmaceuticals Inc.'s market cap?
Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of about $5.04B, based on the latest data in our nightly-refreshed cache.
When does Xenon Pharmaceuticals Inc.'s fiscal year end?
XENE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Xenon Pharmaceuticals Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.